|Title:||Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer|
|Abstract:||The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.|
|Inventor(s):||Helleday; Thomas (Stockholm, SE)|
|Assignee:||The University of Sheffield (Sheffield, GB)|
|Patent Claims:||1. A method of treatment of cancer cells defective in homologous recombination (HR), the method comprising: identifying a human patient with a familial predisposition to gene-linked hereditary cancer, wherein said cancer comprises cancer cells defective in homologous recombination; identifying a compound which inhibits PARP-1, and administering to said human patient a therapeutically effective amount of said compound.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.